Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy

Taxiarchis Kourelis, Shaji K Kumar, Geetika Srivastava, Morie Gertz, Martha Lacy, Francis K. Buadi, Suzanne R. Hayman, Steven R. Zeldenrust, Nelson Leung, Robert A. Kyle, Stephen J Russell, David M Dingli, John A. Lust, Yi Lin, Prashant Kapoor, Ronald Go, S Vincent Rajkumar, Angela Dispenzieri

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

There are no systematic data regarding nonmaintained induction for those patients with multiple myeloma (MM) who do not receive consolidative autologous stem cell transplantation. Of 173 patients with newly diagnosed MM treated with lenalidomide and dexamethasone (LenDex) as primary therapy, 31 patients had their lenalidomide discontinued for reasons other than progression or alternate therapy. Median progression free survival (PFS) from the time of discontinuing lenalidomide was longer in patients who received lenalidomide ≥1 year (39 vs. 13 months, P<0.05); there was no difference in PFS for those treated for 1-2 years as compared to ≥2 years. Among those taking lenalidomide for ≥1 year PFS was superior in patients who were in very good partial response (VGPR) or better as compared to those with partial response (48.4 versus 14.8 months, P<0.05). All patients who progressed and were rechallenged with LenDex responded. These analyses illustrate that discontinuation of lenalidomide after 1 year among those patients achieving a ≥VGPR can result in long-term disease control.

Original languageEnglish (US)
Pages (from-to)302-305
Number of pages4
JournalAmerican Journal of Hematology
Volume89
Issue number3
DOIs
StatePublished - Mar 2014

Fingerprint

Multiple Myeloma
Suspensions
Disease-Free Survival
Dexamethasone
Therapeutics
Stem Cell Transplantation
lenalidomide

ASJC Scopus subject areas

  • Hematology

Cite this

Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. / Kourelis, Taxiarchis; Kumar, Shaji K; Srivastava, Geetika; Gertz, Morie; Lacy, Martha; Buadi, Francis K.; Hayman, Suzanne R.; Zeldenrust, Steven R.; Leung, Nelson; Kyle, Robert A.; Russell, Stephen J; Dingli, David M; Lust, John A.; Lin, Yi; Kapoor, Prashant; Go, Ronald; Rajkumar, S Vincent; Dispenzieri, Angela.

In: American Journal of Hematology, Vol. 89, No. 3, 03.2014, p. 302-305.

Research output: Contribution to journalArticle

@article{2dac4f430d564d7cb5c8c96c08bc3216,
title = "Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy",
abstract = "There are no systematic data regarding nonmaintained induction for those patients with multiple myeloma (MM) who do not receive consolidative autologous stem cell transplantation. Of 173 patients with newly diagnosed MM treated with lenalidomide and dexamethasone (LenDex) as primary therapy, 31 patients had their lenalidomide discontinued for reasons other than progression or alternate therapy. Median progression free survival (PFS) from the time of discontinuing lenalidomide was longer in patients who received lenalidomide ≥1 year (39 vs. 13 months, P<0.05); there was no difference in PFS for those treated for 1-2 years as compared to ≥2 years. Among those taking lenalidomide for ≥1 year PFS was superior in patients who were in very good partial response (VGPR) or better as compared to those with partial response (48.4 versus 14.8 months, P<0.05). All patients who progressed and were rechallenged with LenDex responded. These analyses illustrate that discontinuation of lenalidomide after 1 year among those patients achieving a ≥VGPR can result in long-term disease control.",
author = "Taxiarchis Kourelis and Kumar, {Shaji K} and Geetika Srivastava and Morie Gertz and Martha Lacy and Buadi, {Francis K.} and Hayman, {Suzanne R.} and Zeldenrust, {Steven R.} and Nelson Leung and Kyle, {Robert A.} and Russell, {Stephen J} and Dingli, {David M} and Lust, {John A.} and Yi Lin and Prashant Kapoor and Ronald Go and Rajkumar, {S Vincent} and Angela Dispenzieri",
year = "2014",
month = "3",
doi = "10.1002/ajh.23634",
language = "English (US)",
volume = "89",
pages = "302--305",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy

AU - Kourelis, Taxiarchis

AU - Kumar, Shaji K

AU - Srivastava, Geetika

AU - Gertz, Morie

AU - Lacy, Martha

AU - Buadi, Francis K.

AU - Hayman, Suzanne R.

AU - Zeldenrust, Steven R.

AU - Leung, Nelson

AU - Kyle, Robert A.

AU - Russell, Stephen J

AU - Dingli, David M

AU - Lust, John A.

AU - Lin, Yi

AU - Kapoor, Prashant

AU - Go, Ronald

AU - Rajkumar, S Vincent

AU - Dispenzieri, Angela

PY - 2014/3

Y1 - 2014/3

N2 - There are no systematic data regarding nonmaintained induction for those patients with multiple myeloma (MM) who do not receive consolidative autologous stem cell transplantation. Of 173 patients with newly diagnosed MM treated with lenalidomide and dexamethasone (LenDex) as primary therapy, 31 patients had their lenalidomide discontinued for reasons other than progression or alternate therapy. Median progression free survival (PFS) from the time of discontinuing lenalidomide was longer in patients who received lenalidomide ≥1 year (39 vs. 13 months, P<0.05); there was no difference in PFS for those treated for 1-2 years as compared to ≥2 years. Among those taking lenalidomide for ≥1 year PFS was superior in patients who were in very good partial response (VGPR) or better as compared to those with partial response (48.4 versus 14.8 months, P<0.05). All patients who progressed and were rechallenged with LenDex responded. These analyses illustrate that discontinuation of lenalidomide after 1 year among those patients achieving a ≥VGPR can result in long-term disease control.

AB - There are no systematic data regarding nonmaintained induction for those patients with multiple myeloma (MM) who do not receive consolidative autologous stem cell transplantation. Of 173 patients with newly diagnosed MM treated with lenalidomide and dexamethasone (LenDex) as primary therapy, 31 patients had their lenalidomide discontinued for reasons other than progression or alternate therapy. Median progression free survival (PFS) from the time of discontinuing lenalidomide was longer in patients who received lenalidomide ≥1 year (39 vs. 13 months, P<0.05); there was no difference in PFS for those treated for 1-2 years as compared to ≥2 years. Among those taking lenalidomide for ≥1 year PFS was superior in patients who were in very good partial response (VGPR) or better as compared to those with partial response (48.4 versus 14.8 months, P<0.05). All patients who progressed and were rechallenged with LenDex responded. These analyses illustrate that discontinuation of lenalidomide after 1 year among those patients achieving a ≥VGPR can result in long-term disease control.

UR - http://www.scopus.com/inward/record.url?scp=84896702399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896702399&partnerID=8YFLogxK

U2 - 10.1002/ajh.23634

DO - 10.1002/ajh.23634

M3 - Article

C2 - 24265187

AN - SCOPUS:84896702399

VL - 89

SP - 302

EP - 305

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 3

ER -